Preparation and evaluation of galactosylated vesicular carrier for hepatic targeting of silibinin

Drug Development and Industrial Pharmacy

Volumn 36, Issue 5, 2010, Pages 547-555

  Dube, Devyani ^a   Khatri, Kapil ^a   Goyal, Amit K ^a   Mishra, Neeraj ^a   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Targeting

Indexed keywords

4 AMINOPHENYL BETA DEXTRO GALACTOPYRANOSIDE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOHYDRATE DERIVATIVE; CARBON TETRACHLORIDE; DRUG CARRIER; GALACTOSE; GALACTOSYLATED LIPOSOME; LECTIN RECEPTOR; LIPOSOME; SILIBININ; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DIALYSIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG TISSUE LEVEL; ENCAPSULATION; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER PROTECTION; MALE; NONHUMAN; OXIDATIVE STRESS; PLASMA; RAT; RICINUS COMMUNIS; TISSUE DISTRIBUTION;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; FEMALE; GALACTOSE; LIPOSOMES; LIVER; MALE; RATS; SILYMARIN; TISSUE DISTRIBUTION;

EID: 77952607746     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903325560     Document Type: Article

References (46)

1. Berg T, Boman D. (1973). Distribution of lysosomal enzymes between parenchymal and Kupffer cells of rat liver. Biochim Biophys Acta, 321: 585-96.
2. Sinha J, Das N, Basu MK. (2000). Targeting of glycoside-grafted liposomes to specific hepatocellular sites. J Surf Sci Technol, 16: 200-9.
3. Murao A, Nishikawa M, Managit C, Wong J, Kawakami S, Yamashita F, Hashida M. (2002). Targeting efficiency of galactosylated liposomes to hepatocytes in vivo: Effect of lipid composition. Pharm Res, 19 (12): 1808-14.
4. Hara T, Ishihara H, Aramaki Y, Tsuchiya S. (1988). Specific uptake of asialofetuin-labeled liposomes by isolated hepatocytes. Int J Pharm, 42: 69-75.
5. Tsuchiya S, Aramaki Y, Hara T, Hoshi K, Okada A. (1986). Preparation and disposition of asialofetuin labeled liposomes. Biopharm Drug Dispos, 7: 549-8.
6. Wu J, Liu P, Zhu JL, Maddukuri S, Zern MA. (1998). Increased liver uptake of liposomes and improved targeting efficacy by labeling with asialofetuin in rodents. Hepatology, 27: 772-8.
7. Spanjer HH, Scherphof GL. (1983). Targeting of lactosylceramide- containing liposomes to hepatocytes in vivo. Biochim Biophys Acta, 734: 40-7.
8. Ghosh PC, Bachhawat BK. (1991). Targeting of liposomes to hepatocytes. Targeted Diagn Ther, 4: 87-103.
9. Murahashi N, Ishihara H, Sasaki A, Sakagami M, Hamana H. (1997). Hepatic accumulation of glutamic acid branched neogalactosyllipid modified liposomes. Biol Pharm Bull, 20: 259-66.
10. Kawakami S, Yamashita F, Nishikawa M, Takakura Y, Hashida M. (1998). Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes. Biochem Biophys Res Commun, 252: 78-83.
11. Kawakami S, Fumoto S, Nishikawa M, Yamashita F, Hashida M. (2000). In vivo gene delivery to the liver using novel galactosylated cationic liposomes. Pharm Res, 17: 306-13. (Pubitemid 30225134)
12. Kawakami S, Wong J, Sato A, Hattori Y, Yamashita F, Hashida M. (2000). Biodistribution characteristics of mannosylated, fucosylated and galactosylated liposomes in mice. Biochim Biophys Acta, 1524: 258-65.
13. Nag A, Ghosh PC. (1999). Assessment of targeting potential of galactosylated and mannosylated sterically stabilized liposomes to different cell types of mouse liver. J Drug Target, 6: 427-38.
14. Yamamoto M, Ichinose K, Ishii N, Khoji T, Akiyoshi K, Moriguchi N, et al. (2000). Utility of liposomes coated with polysaccharide bearing 1-amino-lactose as targeting chemotherapy for AH66 hepatoma cells. Oncol Rep, 7: 107-11.
15. Hattori Y, Kawakami S, Yamashita F, Hashida M. (2000). Controlled biodistribution of galactosylated liposomes and incorporated probucol in hepatocyte-selective drug targeting. J Control Release, 69: 369-77.
16. Managit C, Kawakami S, Nishikawa M, Yamashita F, Hashida M. (2003). Targeted and sustained drug delivery using PEGylated galactosylated liposomes. Int J Pharm, 266: 77-84.
17. Wang S, Deng Y, Xu H, Wu H, Qiu Y, Chen D. (2006). Synthesis of a novel galactosylated lipid and its application to the hepatocyte-selective targeting of liposomal doxorubicin. Eur J Pharm Biopharm, 62: 32-8.
18. Han JH, Oh YK, Kim DS, Kim CK. (1999). Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier. Int J Pharm, 188: 39-47.
19. Kawakami S, Munakata C, Fumoto S, Yamashita F, Hashida M. (2001). Novel galactosylated liposomes for hepatocyte-selective targeting of lipophilic drugs. J Pharm Sci, 90: 105-13.
20. Behari JR, Nihal M. (2000). Galactosylated liposomes as carriers for targeting meso-2, 3-dimercaptosuccinic acid to cadmium storage sites in cadmium exposed mice. Ind Health, 38: 408-12.
21. Mandal AK, Das N. (2005). Sugar coated liposomal flavonoid: A unique formulation in combating carbontetrachloride induced hepatic oxidative damage. J Drug Target, 13 (5): 305-15.
22. Flora K, Hahn M, Rosen H, Benner K. (1998). Milk thistle (Silybum marianum) for the therapy of liver diseases. Am J Gastroenterol, 93: 139-43.
23. Valenzuela A, Garrido A. (1994). Biochemical bases of the pharmacological action of the flavonoid silymarin and its structural isomer silibinin. Biol Res, 27: 105-12.
24. Morazzoni P, Bombardelli E. (1999). Silybum marianum (Carduus marianus). Fitoterapia, 66: 3-42.
25. Skottová N, Krěcman V. (1998). Dietary silymarin improves removal of low density lipoproteins by the perfused rat liver. Acta Univ Palacki Olomuc Fac Med, 141: 39-40.
26. Skottová N, Krěcman V, Šimánek V. (1999). Activities of silymarin and its flavonolignans upon low density lipoprotein oxidizability in vitro. Phytother Res, 13: 535-7.
27. Basaga H, Poli G, Tekkaya C, Aras I. (1997). Free radical scavenging and antioxidative properties of 'silibin' complexes on microsomal lipid peroxidation. Cell Biochem Funct, 15: 27-33.
28. Skottová N, Krěcman V, Váňa P, Chmela Z, Ulrichová J, Šimánek V. (2000). Effect of silymarin and silibininphosphatidylcholine complex on plasma and lipoprotein cholesterol, and oxidation of LDL in rats fed on high cholesterol diet supplemented with currant oil. Acta Univ Palacki Olomuc Fac Med, 144: 55-8.
29. El-Samaligy MS, Afifi NN, Mahmoud EA. (2006). Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance. Int J Pharm, 319: 121-9.
30. Ghosh P, Bachawat BK. (1980). Grafting of different glycosides on the surface of liposomes and its effect on tissue distribution of I-labelled globulin encapsulated liposomes. Biochim. Biophys Acta, 632: 562-72.
31. New R R C. (1990). Introduction and preparation of liposomes. In: New RRC, ed. Liposomes: A practical approach. Oxford: Oxford University Press, 1-32.
32. Fry DW, White JC, Goldman ID. (1978). Rapid separation of low molecular weight solutes from liposomes without dilution. Anal Biochem, 90: 809-15.
33. Maheshwari H, Agarwal R, Patil C, Katare OP. (2003). Preparation and pharmacological evaluation of silibinin liposomes. Arzneim-Forsch./Drug Res, 53: 420-7.
34. Vyas SP, Katare YK, Mishra V, Sihorkar V. (2000). Ligand directed macrophage targeting of Amphotericin B loaded liposomes. Int J Pharm, 210: 1-14.
35. Zhao A, Agrawal R. (1999). Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: Implications in cancer chemoprevention. Carcinogenesis, 20: 2101-8.
36. Khatri K, Rawat A, Mahor S, Gupta PN, Vyas SP. (2005). Hepatitis B surface protein docked vesicular carrier for site specific delivery to liver. J Drug Target, 13 (6): 359-66.
37. Saraf S, Dixit VK. (1991). Hepatoprotective activity of Tridax procumbens - Part II. Fitoterapia, 11 (6): 534-6.
38. Moribe K, Maruyama K, Iwatsuru M. (2000). Spectroscopic investigation of the molecular state of nystatin encapsulated in liposomes. Int J Pharm, 201: 37-49.
39. Gabetta B, Bombardelli E, Pifferi G. (1988). Complexes of flavanolignans with phospholipids, preparation thereof and associated pharmaceutical compositions. US patent no. 4, 764, 508, 16.
40. Comoglio A, Tomasi A, Malandrino S, Poli G, Albano E. (1995). Scavenging effect of silipide, a new silybin-phospholipid complex on ethanol-derived free radicals. Biochem Pharm, 50: 1313-6.
41. Ahsan F, Rivas IP, Khan MA, Suarez A I T. (2002). Targeting to macrophages: Role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release, 79: 29-40.
42. Datta N, Mukherjee S, Das L, Das PK. (2003). Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide upregulation and T-cell activation. Eur J Immunol, 33: 1508-18.
43. Pagano RE, Weinstein JN, (1978). Interactions of liposomes with mammalian cells. Ann Rev Biophys Bioeng, 7: 435-68.
44. Garcon N, Gregoriadis G, Taylor M, Summerfield J. (1988). Mannose-mediated targeted immunoadjuvant action of liposomes. Immunology, 64 (4): 743-5.
45. Medda S, Mukherjee S, Das N, Naskar K, Mahato SB, Basu MK. (1993). Sugar-coated liposomes: A novel delivery system for increased drug efficacy and reduced drug toxicity. Biotechnol Appl Biochem, 17: 37-47.
46. Raay B, Medda S, Mukhopadhyay S, Basu MK. (1999). Targeting of piperine intercalated in mannose-coated liposomes in experimental leishmaniasis. Indian J Biochem Biophys, 36 (4): 248-51.